摘要
目的比较莫西沙星与左氧氟沙星在治疗青年耐多药肺结核病(MDR-PTB)中的疗效与安全性。方法选择青年MDR-PTB患者84例,随机分为两组。所有患者均给予相同的抗结核药物治疗,对照组患者加服左氧氟沙星片0.6 g/d,试验组患者加服莫西沙星片0.4 g/d,疗程均为12个月。观察两组痰结核杆菌阴转情况、疗效及不良反应发生情况。结果试验组在治疗3、6、9、12个月时,结核杆菌阴转率均显著高于对照组(P<0.05),总有效率(90.48%)也显著高于对照组(54.76%)(P<0.05),而两组不良反应发生率无统计学差异(P>0.05)。结论莫西沙星较左氧氟沙星治疗青年MDR-PTB疗效更好,且安全可靠。
Objective To make comparison of the curative effect and safety between moxifloxacin and levofloxacin in the treatment of young patients with muhi-dtug resistant pulmonary tuberculosis （MDR-trI＇B）. Methods Eighty four young patients with MDR-PTB were enrolled in the study and randomly divided into two groups. All the patients received the same conventional anti-TB treatment. The control group was also additionally given levofloxacin （0.6 g/d ）, and the experimental group was given additionally moxifloxacin（0.4 g/d）. The course of treatment was both 12 months. Observation was made in the negative conversion of sputum bacillus tuberculosis, curative effect, and adverse reactions. Results The rate of sputum bacillus tuberculosis negative conversion in the experimental group were significantly higher than that in the control group respectively 3,6,9 ,and 12 months after the treatment（ P 〈 0.05 ） , and the total effective rate was 90.48% in the experimental group, which was also significantly higher than that in the control group（54.76% ）（P 〈0.05）. There was no significant difference in the incidence of adverse reactions between the two groups（ P 〉 0.05 ）. Conclusion Moxifloxacin has superior curative effect to levofloxacin on young patients with MDR-PTB and is safer and more reliable.
出处
《西南国防医药》
CAS
2014年第1期38-41,共4页
Medical Journal of National Defending Forces in Southwest China
关键词
莫西沙星
左氧氟沙星
耐多药
肺结核
疗效
moxifloxacin
levofloxacin
multi-drug resistant
pulmonary tuberculosis
curative effect
